Clinical characteristics and prognostic analysis of primary extranodal non-Hodgkin lymphoma of the head and neck

Abstract

Objective: Primary extranodal non-Hodgkin's lymphoma (PE-NHL) of the head and neck is the second common site of extranodal lymphoma, accounting for approximately one-third of all extranodal non-Hodgkin's lymphoma (E-NHL). However, in recent years, large-scale PE-NHL case studies in China and worldwide are rare and not comprehensive enough. This work analyzed the clinical manifestations, pathological features, immunophenotypes and diagnosis of PE-NHL, as well as the factors affecting the treatment and prognosis.

Methods: A retrospective study was performed on 74 patients who were diagnosed with head and neck PE-NHL and treated for the first time. The clinical manifestations, pathological features, and immunophenotypes were summarized, and the factors related to the treatment and prognosis were analyzed.

Results: The most common site of this disease was the Waldeyer's ring, followed by the nasal cavity. Diffuse large B-cell lymphoma was the most common type, followed by extranodal NK T-cell lymphoma nasal type. The 1-year, 2-year, and 5-year progression-free survival (PFS) rates were 76.4%, 67.9%, and 59.3%. The 1-year, 2-year, and 5-year overall survival (OS) rates were 89.4%, 85.6%, and 63.2%. ECOG score ≥ 2, Ann Arbor stage III or IV and IPI risk stratification identifying patients as the high-risk group were independent risk factors affecting the OS of patients with PE-NHL of the head and neck.

Conclusions: The most common site of PE-NHL in these Chinese patients was the Waldeyer's ring, but the incidence in the nasal cavity was higher than that reported in Western countries. Radiotherapy combined with chemotherapy had better efficacy than chemotherapy alone, and the prognosis depended on the ECOG score and clinical stage. IPI had a better prognostic value in patients in the high-risk group of head and neck PE-NHL.

Keywords: clinical characteristics; extranodal non-Hodgkin’s lymphoma; head and neck neoplasms; primary; prognostic factor.

Figure 1

(A–D) Immunohistochemistry, medium magnification (×20), (A) Ki-67+, (B) Bcl-2+, (C) Bcl-6+, (D) MuM-1+.

Figure 2

ORR of patients with PE-NHL of the head and neck under different treatment methods.

Figure 3

Kaplan Meier plots of the overall survival (A) and progression free survival (B) of all patients. Kaplan Meier plots of the overall survival and progression free survival by ECOG score (C, D), Ann Arbor stage (E, F), B symptoms (G, H), and IPI risk group stratification (I, J).